GlassScriptPhysician profile
Michael H Verdolin
NPI 1477525657
$506,681.73
in general payments reported to CMS, 2019-2025
26 companies · $3,789 in 2025
The $3,789 reported for 2025 was more than what 88% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149K · 2020: $136K · 2021: $78K · 2022: $46K · 2023: $88K · 2024: $7,106 · 2025: $3,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $78K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,630 · Food and Beverage: $7,063 · Travel and Lodging: $3,291 · Debt Forgiveness: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $77,635.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,630.00 |
| Food and Beverage | $7,063.05 |
| Travel and Lodging | $3,290.91 |
| Debt Forgiveness | $1,269.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $172,740.09 | 2019-2020 | |
| Boston Scientific Corporation | $157,701.26 | 2019-2022 | |
| Vertos Medical, INC. | $108,727.91 | 2020-2024 | Mild Device Kit |
| Abbott Laboratories | $35,517.22 | 2020-2025 | Proclaim, Octrode, Eterna |
| Vertiflex, INC. | $11,804.17 | 2019 | |
| Medtronic, INC. | $9,543.26 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Spinal Simplicity, LLC | $3,489.28 | 2021-2023 | Ha Minuteman G3-R |
| Painteq LLC | $2,823.38 | 2021-2024 | Painteq |
| Bioventus LLC | $1,269.60 | 2024 | Durolane |
| Saluda Medical Americas, INC. | $1,159.24 | 2022-2025 | Evoke Scs, Evoke |
| Mml US, INC. | $631.34 | 2021-2023 | Reactiv8 |
| Nevro Corp. | $357.06 | 2023 | Senza |
| Stryker Corporation | $180.06 | 2019-2024 | Mild Device Kit |
| Stimwave Technologies Incorporated | $175.78 | 2021-2022 | |
| Biotronik Nro, INC. | $173.16 | 2023 | Biotronik |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $124.25 | 2021 | |
| Abbvie INC. | $48.90 | 2021 | |
| Allergan, INC. | $34.26 | 2020 | |
| Intrinsic Therapeutics | $30.71 | 2025 | Barricaid Acd (Annular Closure Device) |
| Depuy Synthes Sales INC. | $29.91 | 2023 | Orthovisc |
| Si-Bone, INC. | $26.45 | 2024 | |
| Piramal Critical Care | $24.32 | 2019 | |
| Curonix LLC | $22.35 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $20.50 | 2021 | |
| Foundation Fusion Solutions, LLC | $13.71 | 2023 | |
| Merz Pharmaceuticals, LLC | $13.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Verdolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.